康方生物的AK112_老虎社区_美港股上老虎

康方生物的AK112头对头击败K药之后，维立志博的LBL-024再次验证了双抗“1+1>2”的临床价值。双抗替代单抗的浪潮已经来了，滚雪球才刚刚开始。 $维立志博-B(09887)$ $康方生物(09926)$

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":461554116465000,"tweetId":"461554116465000","gmtCreate":1753707491498,"gmtModify":1753707745667,"author":{"id":9000000000000228,"idStr":"9000000000000228","authorId":9000000000000228,"authorIdStr":"9000000000000228","name":"重生之我是鲍威尔","avatar":"https://static.tigerbbs.com/b610f7fa83d7281fe00c102df34d1691","vip":8,"userType":8,"introduction":"简介","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":32,"starInvestorFlag":false},"themes":[{"themeId":"ea79df3ca11c411d857d85195aaee090","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"维立志博-B首日近翻倍！能否继续持有？","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":ea79df3ca11c411d857d85195aaee090}&rnconfig={\"headerBarHidden\": true}","description":"维立志博-B于7月25日在港交所上市，盘中一度升近130%，收涨超91%，总市值近130亿港元。【大家还看好该股后续涨势吗？你会继续持有吗？】","image":"https://static.tigerbbs.com/6239c374134a0434b9f014259b5179ad"}],"images":[],"coverImages":[],"html":"<html><head></head><body><p>康方生物的AK112头对头击败K药之后，维立志博的LBL-024再次验证了双抗“1+1&gt;2”的临床价值。双抗替代单抗的浪潮已经来了，滚雪球才刚刚开始。 <a data-mention-id=\"09887\" class=\"teditor-mention\" data-mention-name=\"维立志博-B\" href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a>  <a data-mention-id=\"09926\" class=\"teditor-mention\" data-mention-name=\"康方生物\" href=\"https://laohu8.com/S/09926\">$康方生物(09926)$</a> </p></body></html>","htmlText":"<html><head></head><body><p>康方生物的AK112头对头击败K药之后，维立志博的LBL-024再次验证了双抗“1+1&gt;2”的临床价值。双抗替代单抗的浪潮已经来了，滚雪球才刚刚开始。 <a data-mention-id=\"09887\" class=\"teditor-mention\" data-mention-name=\"维立志博-B\" href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a>  <a data-mention-id=\"09926\" class=\"teditor-mention\" data-mention-name=\"康方生物\" href=\"https://laohu8.com/S/09926\">$康方生物(09926)$</a> </p></body></html>","text":"康方生物的AK112头对头击败K药之后，维立志博的LBL-024再次验证了双抗“1+1>2”的临床价值。双抗替代单抗的浪潮已经来了，滚雪球才刚刚开始。 $维立志博-B(09887)$ $康方生物(09926)$","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/461554116465000","repostId":0,"isVote":1,"tweetType":1,"viewCount":1798,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["09926","09887"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":true,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":162,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}